Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Integrated incremental immunoreactive insulin and connecting peptide responses to an oral glucose load of 50 g and an "isoglycaemic" intravenous glucose infusion, respectively, were measured in 14 Type 2 (non-insulin-dependent) diabetic patients and 8 age- and weight-matched metabolically healthy control subjects. Differences between responses to oral and intravenous glucose administration are attributed to factors other than glucose itself (incretin effect). Despite higher glucose increases, immunoreactive insulin and connecting peptide responses after oral glucose were delayed in diabetic patients. Integrated responses were not significantly different between both groups. However, during "isoglycaemic" intravenous infusion, insulin and connecting peptide responses were greater in diabetic patients than in control subjects as a consequence of the higher glycaemic stimulus. The contribution of incretin factors to total insulin responses was 72.8 +/- 6.9% (100% = response to oral load) in control subjects and 36.0 +/- 8.8% in diabetic patients (p less than or equal to 0.05). The contribution to connecting peptide responses was 58.4 +/- 7.6% in control subjects and 7.6 +/- 14.5% (p less than or equal to 0.05) in diabetic patients. Ratios of integrated insulin to connecting peptide responses suggest a reduced (hepatic) insulin extraction in control subjects after oral as compared to intravenous glucose. This was not the case in diabetic patients. Immunoreactive gastric inhibitory polypeptide responses were not different between control subjects and diabetic patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16,17,18].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“People with obesity and/or T2D have impaired incretin release ( Toft-Nielsen et al., 2001 ; Vilsbøll et al., 2001 ) and/or function ( Nauck et al., 1986 ; Muscelli et al., 2008 )”
From Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes (2024) · cites this paper as Nauck et al., 1986
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917 · cited 2×
“Thus the study of Perley and Kipnis [ 10 ] from 1967 does not - in the absence of C-peptide measurements - allow final conclusions about the incretin effect in Type 2 diabetic patients.”
BackgroundSeltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 5×
“In healthy young subjects, a clear dose-dependency of incretin effects after oral glucose has been observed [6].”
BackgroundResultInfluentialSelf-citationRadioimmunological determination of human C-peptide in serum
Heding, L. G. (1975) · Diabetologia · doi:10.1007/bf01222104 · Cited by 830
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2].”
BackgroundSelf-citationThe Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
Garvey, W. T., Olefsky, J. M., Griffin, J., Hamman, R. F., & Kolterman, O. G. (1985) · Diabetes · doi:10.2337/diab.34.3.222 · Cited by 488 · cited 1×
“Arguing against this explanation, intravenous isoproterenol [36] or glucagon [ 37 ] enhanced, rather than diminished, additional B cell secretory responses in Type 2 diabetic patients when plasma glucose levels had been elevated by glucose infusion up to the range employed in our study.”
ResultC-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations
Polonsky, K. S., & Rubenstein, A. H. (1984) · Diabetes · doi:10.2337/diab.33.5.486 · Cited by 476 · cited 3×
“This conclusion must, however, remain speculative because of reservations regarding the "insulin to C-peptide ratio method" for estimating changes in (hepatic) insulin extraction [ 33 ].”
BackgroundMethodInfluentialTHE PLASMA INSULIN RESPONSE TO GLUCOSE INFUSION IN HEALTHY SUBJECTS AND IN DIABETES MELLITUS
Cerasi, E., & Luft, R. (1967) · Acta Endocrinologica · doi:10.1530/acta.0.0550278 · Cited by 371 · cited 2×
“The markedly reduced incretin effect found in our group with a more severe degree of Type 2 diabetes may simply be an expression of their impaired capacity to secrete insulin at an adequate rate [3, 4 ]. The glycaemic stimulus with plasma glucose values of -17mmol/1 (300mg/dl) may already have led to maximal B cell st…”
BackgroundUnger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2 ].”
Background
Research works printed but not linked: 4
- Bloom SR (1975) GIP in diabetes (abstract). Diabetologia 11: 334
- WHO Expert Committee on Diabetes Mellitus, Second Report, Technical Report Series 646, WHO, Geneva, 1980
- Madison LL, Kaplan N (1958) The hepatic binding of I-131 labeled insulin in human subjects during a single transhepatic circulation. J Lab Clin Med 52: 927–932
- Ross SA, Brown JC, Dupre J (1974) Effects of Gastric Inhibitory Polypeptide on endocrine pancreas in normal and diabetic subjects. Diabetologia 10: 384 (Abstract)
Cited by
Items 901–1,000 of 1,001
Incretins in the ICU: is insulin on its way out?
Kovalaske, M. A., & Gandhi, G. Y. (2009) · Critical Care · doi:10.1186/cc7913 · Cited by 6
“Patients with type 2 diabetes have a reduced incretin effect [7].”
BackgroundGu, N., Cho, S., Kim, J. W., Shin, D., Seol, E., Lee, H., Lim, K. S., Shin, S., Jang, I., & Yu, K. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.12.002 · Cited by 7
Who needs an artificial pancreas? (怎样的患者需要一个人工胰腺?)
Winikoff, J., & Drexler, A. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12052 · Cited by 6
Li, P., Zhu, L., Wang, G., Yang, X., Yi, B., & Zhu, S. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.01.009 · Cited by 6
“The effect of incretins on either glucose or lipid metabolism was shown to be impaired in T2DM patients [12].”
BackgroundIn Vivo Models for Incretin Research: From the Intestine to the Whole Body
Oh, T. J. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.1.45 · Cited by 8
Cardiometabolic effects of antidiabetic drugs in non‐alcoholic fatty liver disease
Rix, I., Pedersen, J. S., Storgaard, H., & Gluud, L. L. (2018) · Clinical Physiology and Functional Imaging · doi:10.1111/cpf.12526 · Cited by 8
“Patients with type 2 diabetes exhibit impaired GLP-1–induced insulin secretion in response to oral food intake contributing to their glucose intolerance (Nauck et al., 1986).”
BackgroundHasegawa, T., 駒形美穂, Hamasaki, A., Harada, N., Seino, Y., & Inagaki, N. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12896 · Cited by 7
“(1), Millipore ELISA Kit; (2), IBL ELISA kit.”
MethodHædersdal, S., Lund, A., Nielsen-Hannerup, E., Maagensen, H., Forman, J. L., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0291 · Cited by 6
Formiga, F., Gómez‐Huelgas, R., & Rodríguez‐Mañas, L. (2015) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2015.04.002 · Cited by 18
Type 2 Diabetes Mellitus: Epidemiology, Genetics, Pathogenesis, and Clinical Manifestations
Fonseca, V. A., & John‐Kalarickal, J. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_13 · Cited by 13
Linagliptin for the treatment of Type 2 diabetes
Tella, S. H., Aktürk, H. K., & Rendell, M. (2013) · Diabetes Management · doi:10.2217/dmt.13.55 · Cited by 6
Htike, Z. Z., Zaccardi, F., Chatterjee, S., Khunti, K., & Davies, M. J. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.091 · Cited by 6
Duodenal L cell density correlates with features of metabolic syndrome and plasma metabolites
van Baar, A. C. G., Prodan, A., Wahlgren, C. D., Poulsen, S. S., Knop, F. K., Groen, A. K., Bergman, J. J. G. H. M., Nieuwdorp, M., & Levin, E. (2018) · Endocrine Connections · doi:10.1530/ec-18-0094 · Cited by 6
Kang, M., Fěng, F., Ge, Q., Zhu, F., Chen, L., Lv, P., Ma, S., Yao, Q., & Chen, K. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.14729 · Cited by 6
Recent Updates on Glucagon-Like Peptide 1 Receptor Agonist
Kim, H. J. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.22.2.126 · Cited by 7
Gliptins: DPP‐4 inhibitors to treat type 2 diabetes
Green, B., Flatt, P. R., & Bailey, C. J. (2007) · Future Prescriber · doi:10.1002/fps.33 · Cited by 9
Gautier, J., & Sauvanet, J.-P. (2011) · Annales d Endocrinologie · doi:10.1016/j.ando.2011.05.005 · Cited by 6
Influence of Glycemic Control on the Development of Diabetic Cardiovascular and Kidney Disease
Saha, S. A., & Tuttle, K. R. (2010) · Cardiology Clinics · doi:10.1016/j.ccl.2010.04.008 · Cited by 8
β‐Cell mass and function in human type 2 diabetes
Marchetti, P., & Ferrannini, E. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch24 · Cited by 13
Effect of intestinal factors on extraction of insulin in perfused rat liver
Ikeda, T., Yoshida, T., Honda, M., Ito, Y., Murakami, I., Mokuda, O., Tominaga, M., & Mashiba, H. (1987) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1987.253.6.e603 · Cited by 6
Åhrén, B. (2014) · Regulatory Peptides · doi:10.1016/j.regpep.2014.09.003 · Cited by 6
“in 1964 [10,11], Perley and Kipnis in 1967 [12] and Nauck and collaborators in 1986 [13].”
BackgroundThe Dynamic Incretin Adaptation and Type 2 Diabetes
Åhrén, B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0299 · Cited by 6
“iv glucose when plasma glucose levels were matched, and the study was performed in both healthy subjects and subjects with type 2 diabetes (10).”
MethodCreutzfeldt, W., & Ebert, R. (1988) · Advances in metabolic disorders · doi:10.1016/b978-0-12-027311-9.50014-7 · Cited by 8
Self-citationCandido, R., Toffoli, B., Baccichetto, G., Marchese, F., Carpenè, S., Gaiotti, S., Fabris, B., & Bernardi, S. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02626-9 · Cited by 5
“Despite reduced endogenous GLP1 levels in T2DM [2], GLP1-R function is preserved.”
Leahy, J. L., & Pratley, R. E. (2011) · Translational endocrinology & metabolism · doi:10.1210/team.9781879225824.ch1 · Cited by 9
Gunta, U., Kandula, D. R., Gorti, S. K. K., Vadla, G. P., Kodiyala, G., & Mannarapu, M. (2023) · Oriental Journal Of Chemistry · doi:10.13005/ojc/390306 · Cited by 5
Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
Spellman, C. (2012) · PubMed · Cited by 5
Takayanagi, R., Uchida, T., Kimura, K., & Yamada, Y. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2057 · Cited by 5
No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect
Mathiesen, D. S., Bagger, J. I., Hansen, K. B., Junker, A. E., Plamboeck, A., Østoft, S. H., Idorn, T., Hornum, M., Holst, J. J., Jonsson, A. E., et al. (2020) · Endocrine Connections · doi:10.1530/ec-20-0471 · Cited by 5
Novel approaches to pharmacological management of type 2 diabetes in Japan
Kaneko, S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1974401 · Cited by 6
“Both GIP and GLP-1 are secreted by the digestive tract in response to ingestion of food [32,33].”
BackgroundSakornyutthadej, N., Mahachoklertwattana, P., Chanprasertyothin, S., Pongratanakul, S., Khlairit, P., & Poomthavorn, P. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13303 · Cited by 6
A collectanea of food insulinaemic index: 2023
Hendricks, S. A., Paul, M. J., Subramaniam, Y., & Vijayam, B. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.06.017 · Cited by 6
Oh, T. J., Park, K. S., & Cho, Y. M. (2014) · Clinical Endocrinology · doi:10.1111/cen.12623 · Cited by 6
The importance of incretin therapies for managing type 2 diabetes
Garber, A. J. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70157-8 · Cited by 5
Incretin Effect in Women with Former Gestational Diabetes within a Short Period after Delivery
Pacini, G., Tura, A., Winhofer, Y., & Kautzky‐Willer, A. (2012) · International Journal of Endocrinology · doi:10.1155/2012/247392 · Cited by 5
“In type 2 diabetic patients, a reduction of this effect has been reported [3, 4] and”
BackgroundMethodVilchis‐Reyes, M. A., & Hanessian, S. (2015) · Topics in heterocyclic chemistry · doi:10.1007/7081_2015_191 · Cited by 5
The safety of albiglutide for the treatment of type 2 diabetes
Rendell, M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1351538 · Cited by 6
A paradigm shift for the prevention and treatment of individual and global obesity
Slyper, A. H. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s183777 · Cited by 6
“GLP-1 is also an incretin and may be responsible for almost half of postprandially secreted insulin.(17) Metformin is commonly used as a first-line treatment for diabetes, and it has mild weight control properties through its ability to influence appetite.”
BackgroundNauck, M. A., Holle, H., Kahle, M., Tytko, A., Deacon, C. F., Holst, J. J., & Meier, J. J. (2019) · Peptides · doi:10.1016/j.peptides.2019.170176 · Cited by 5
Self-citationPhysiology, Gastric Inhibitory Peptide
Gupta, K., & Raja, A. (2019) · StatPearls · Cited by 13
The Effect of Pituitary Gland Disorders on Glucose Metabolism: From Pathophysiology to Management
Sydney, G. I., Michalakis, K. G., Nikas, I. P., Spartalis, E. D., & Paschou, S. Α. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1258-8625 · Cited by 5
“In T2DM, the release of intestinal hormones such as GLP-1 is inhibited, thus leading to an increase in the post-prandial glycemic state [72].”
BackgroundManell, E., Puuvuori, E., Svensson, A. C., Velikyan, I., Hulsart‐Billström, G., Hedenqvist, P., Holst, J. J., Jensen‐Waern, M., & Eriksson, O. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-002083 · Cited by 11
Watkins, J. D., Smith, H., Hengist, A., Brunsgaard, L. H., Mikkelsen, U. R., Koumanov, F., Betts, J. A., & Gonzalez, J. T. (2021) · British Journal Of Nutrition · doi:10.1017/s000711452100297x · Cited by 5
Zhang, M., Zhang, S., Yu, Z., Yao, X., Lei, Z., Yan, P., Wu, N., Wang, X., Hu, Q., & Liu, D. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106553 · Cited by 5
Incretins: the novel therapy of type 2 diabetes.
Thongtang, N., & Sriwijitkamol, A. (2008) · PubMed · Cited by 6
Current challenges in type 2 diabetes
Garber, A. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01572.x · Cited by 5
“Early studies found that the incretin effect is blunted in subjects with T2D, with GLP-1 secretion substantially lower than normal [13,14]; however, a recent meta-analysis has suggested that instead of a reliable progressive decline in the”
ResultSitagliptin and metformin – novel combination therapy
Seyoum, B. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.556113 · Cited by 6
“One of the main possible explanations for the decline in insulin secretion and unabated glucagon secretion is the diminished incretin effect [8].”
BackgroundThe Contribution of Enteroinsular Hormones to the Pathogenesis of Type 2 Diabetes Mellitus
Diab, D. L., & D’Alessio, D. A. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0114-6 · Cited by 8
Incretin secretion in obese Korean children and adolescents with newly diagnosed type 2 diabetes
Park, S. H., Jung, M. H., Cho, W. K., Park, M. S., & Suh, B. (2015) · Clinical Endocrinology · doi:10.1111/cen.12802 · Cited by 5
Martin, C. L. (2008) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721708319238 · Cited by 5
“For patients with type 2 diabetes, there is a marked blunting of gut-mediated augmentation of insulin secretion, prompting the hypothesis that a defect in the incretin response may contribute to the pathophysiology of type 2 diabetes.(8) To further study the reduced incretin effect in diabetes, another investigation o…”
Epidemiology of Type 2 Diabetes and Dementia
Gustafson, D., & McFarlane, S. I. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809454-9.00002-0 · Cited by 6
Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
Journal, C. (2008) · Core evidence · doi:10.2147/ce.s7443 · Cited by 6
Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_12 · Cited by 5
Self-citationDoggrell, S. A. (2007) · Reviews on Recent Clinical Trials · doi:10.2174/157488707779318053 · Cited by 5
“The incretin response to GLP-1 is lost in type 2 diabetes [8].”
BackgroundPathogenesis of Type 2 Diabetes
Cusi, K. J., & DeFronzo, R. A. (2001) · Wiley eBooks · doi:10.1002/cphy.cp070237 · Cited by 6
Dhesi, B., Chauhan, H., & Basu, A. (2013) · Practical Diabetes · doi:10.1002/pdi.1767 · Cited by 4
Role of endogenous incretin hormones, GLP-1 and GIP, in cardiovascular physiology
Trivedi, K., & Dolinsky, V. W. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0163 · Cited by 7
GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients
Montoya, P. A., Evelyn, B., Folino, C., & Allo, Y. J. M. (2020) · Current Hypertension Reviews · doi:10.2174/1573402116999201124123549 · Cited by 4
Sridhar, A., Khan, D., Babu, G., Irwin, N., Gault, V. A., Flatt, P. R., & Moffett, R. C. (2024) · Peptides · doi:10.1016/j.peptides.2024.171254 · Cited by 6
Holst, J. J. (2024) · The Journal of Physiology · doi:10.1113/jp287461 · Cited by 5
Obesity Context of Type 2 Diabetes and Medication Perspectives
Pandit, A., & Pandey, A. K. (2016) · Apollo Medicine · doi:10.1016/j.apme.2015.08.001 · Cited by 4
Pujante, P., Gil, M. D. H., Román, L. M., Gómez, M. F., Zafra, M. V. G., & Massó, J. T. (2011) · Medicina Clínica · doi:10.1016/j.medcli.2011.10.025 · Cited by 4
“Se redujeron de forma no significativa el colesterol total (una media de 4,9 [1,5] mg/dl), el colesterol unido a lipoproteı́nas de baja densidad (colesterol LDL) (una media de 3,2 [3,4] mg/dl, el colesterol unido a lipoproteı́nas de no alta densidad (de 8,6 [5,6] mg/dl) y el colesterol unido a lipoproteı́nas de alta d…”
BackgroundMethodInfluentialSimpson, R., & King, A. B. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1017562 · Cited by 4
“In patients with T2D, the actions of GLP-1 are blunted, and this might contribute to poor glycemic control [17].”
BackgroundIncretins and Regulation of Insulin Secretion
Nauck, M. A., & Meier, J. J. (2008) · Springer eBooks · doi:10.1007/978-4-431-75452-7_17 · Cited by 4
Self-citationASGE EndoVators Summit: Defining the role and value of endoscopic therapies in obesity management
Ryou, M. K., McQuaid, K. R., Thompson, C. C., Edmundowicz, S. A., Mergener, K., Dayyeh, B. A., Apovian, C. M., Burke, C. A., Chand, B., Chandraker, A. K., et al. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.08.024 · Cited by 7
Role of probiotics in the prevention and management of diabetes and obesity
Mallappa, R. H., Balasubramaniam, C., Amarlapudi, M. R., Kelkar, S., Adewumi, G. A., Kadyan, S., Pradhan, D., & Grover, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823733-5.00006-4 · Cited by 4
Åhrén, B. (2023) · Biomedicines · doi:10.3390/biomedicines11020591 · Cited by 5
“A similar magnitude of contribution by the incretin effect on the insulin response to oral glucose has been demonstrated in humans [4,5,26,27].”
BackgroundTirzepatide for the Treatment of Heart Failure in Type 2 Diabetes Mellitus: (SUR)PASS, or Not?
Patoulias, D., Dimosiari, A., & Fragakis, N. (2023) · Future Cardiology · doi:10.2217/fca-2022-0112 · Cited by 4
Myat, A., Arri, S. S., Bhatt, D. L., Gersh, B. J., Redwood, S. R., & Marber, M. S. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0193-4 · Cited by 4
“Despite these properties, the pharmaco-therapeutic utility of native GLP-1 in T2DM is profoundly limited by its rapid inactivation by the enzyme dipeptidyl dipeptidase-4 (DPP-4), which cleaves 2 amino terminal peptides from GLP-1 (7-36 7-36 ) to form The GLP-1R is a heptahelical G-protein coupled receptor found widely…”
BackgroundAndo, T., Hatada, K., Sata, M., Tachiki, H., Fukazawa, T., Kusumoto, S., Horie, I., Abiru, N., Matsumoto, S., & Kawakami, A. (2018) · Acta medica Nagasakiensia · doi:10.11343/amn.61.151 · Cited by 5
“These drugs are known to enhance insulin secretion and also to suppress glucagon following food intake (13,14).”
BackgroundInfluentialHupfeld, C. J., & Olefsky, J. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00040-8 · Cited by 9
Hayami, T., Yokoi, N., Yamaguchi, T., Honda, K., Murao, N., Takahashi, H., Wang, S., Seino, Y., Kamiya, H., Yabe, D., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13272 · Cited by 5
Tura, A., Göbl, C. S., Vardarli, I., Pacini, G., & Nauck, M. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-06402-5 · Cited by 5
Self-citationVadmand, A. C., Nissen, A. A., Mathiesen, S., Sørum, M. E., Gerbek, T., Fridh, M. K., Sørensen, K., Hartmann, B., Holst, J. J., & Müller, K. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac561 · Cited by 4
The incretin system in type 2 diabetes mellitus: cardiovascular effects
Sukhareva, O. Y., Шмушкович, И. А., Shestakova, E. A., & Shestakova, M. V. (2013) · Problems of Endocrinology · doi:10.14341/probl201258633-42 · Cited by 6
Treatment Strategies for Type 2 Diabetes Based on Incretin Action
Gallwitz, B., & Nauck, M. A. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-13 · Cited by 5
Self-citationNew treatments for type 2 diabetes mellitus: combined therapy with sitagliptin
Gagliardino, J. J., Santoro, S., Arellano, S., & Girolamo, G. D. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.9.1495 · Cited by 4
Dipeptidyl peptidase-IV inhibitors: fixing type 2 diabetes?
McIntyre, H. F., & Grant, P. S. (2007) · British Journal of Hospital Medicine · doi:10.12968/hmed.2007.68.11.27682 · Cited by 4
Glucagon and Glucagon‐like Peptide Production and Degradation
Kieffer, T. J., Hussain, M. A., & Habener, J. F. (2001) · Comprehensive physiology · doi:10.1002/cphy.cp070208 · Cited by 5
Fehmann, H.-C., Schweinfurth, J., Jiang, J., & Göke, B. (1996) · Research in Experimental Medicine · doi:10.1007/bf02576844 · Cited by 6
De la découverte des hormones incrétines aux doubles et triples agonistes GIP / GLP-1 / glucagon
Phan, F., Bertrand, R., Amouyal, C., & Andréelli, F. (2024) · médecine/sciences · doi:10.1051/medsci/2024153 · Cited by 4
Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders
Qiao, Y., Zhou, F., Mao, T., & Gao, L. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s559587 · Cited by 4
“Primarily, this is because in individuals with type 2 diabetes (T2DM), 6,7 GIP levels are not substantially diminished, yet GIP receptor signaling is impaired, rendering exogenous GIP supplementation ineffective.”
Alogliptin + metformin combination for the treatment of type 2 diabetes mellitus
Neumiller, J. J., & Holland, D. Q. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1110484 · Cited by 3
“The American Diabetes Association (ADA) provides general recommendations for the use of antihyperglycemic therapies in T2DM.”
BackgroundInfluentialCardiovascular Outcomes Trials of Incretin-Based Therapies
Thethi, T. K., Bilal, A., & Pratley, R. E. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0072 · Cited by 3
Ünlü, Y., Vinales, K. L., Hollstein, T., Chang, D. C., de Baca, T. C., Walter, M. F., Krakoff, J. A., & Piaggi, P. (2022) · Obesity · doi:10.1002/oby.23584 · Cited by 3
“Peripheral GLP-1 is most commonly associated with gastrointestinal secretion and motility and augmentation of insulin secretion, such that 50% of the total glucose-dependent insulin secretion is ascribable to the effects of GLP-1, the so-called “incretin” effect [34, 35].”
BackgroundHelsted, M. M., Gasbjerg, L. S., Vilsbøll, T., Nielsen, C. K., Forman, J. L., Christensen, M., & Knop, F. K. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-065736 · Cited by 3
Rangwala, H. S., Fatima, H., Ali, M., Mustafa, M. S., Shafique, M. A., Rangwala, B. S., & Abbas, S. R. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01412-8 · Cited by 3
“The incretin effect is notably diminished in individuals with DM2 [11 ].”
Hamasaki, A., Harada, N., Muraoka, A., Yamane, S., Joo, E., Suzuki, K., & Inagaki, N. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1301352 · Cited by 3
“Although, the incretin effect was slightly smaller in the T2D group than in the NGT group, the difference was not signi fi cant in contrast to previous reports in Western Caucasians (6 – 11).”
BackgroundMethodResultInfluentialHadid, S. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000940 · Cited by 3
New Perspectives in Modulating the Entero-Insular Axis in Pediatric Obesity
Dira, L.-M., Marin, L.-M., Popa, S. G., Singer, C.-E., Coşoveanu, C. S., Donoiu, I., & Golli, A. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136143 · Cited by 4
“Knop F. K., similar to Nauck M. et al., demonstrated that in adults with type 2 diabetes, the incretin response is reduced [71,72].”
Chapter 8 Calcium dysregulation, insulin release and the pathogenesis of diabetes
Bergsten, P. (2002) · Advances in cell aging and gerontology · doi:10.1016/s1566-3124(02)10020-4 · Cited by 3
Unger, J., Hinnen, D., Schreiner, B., & Parkin, C. (2013) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2012.00736.x · Cited by 4
Predicting response to incretin-based therapy
Kalra, S., Kalra, B., Sahay, R. K., & Agrawal, N. K. (2011) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s16282 · Cited by 3
Lifante, J.-C., & Inabnet, W. B. (2008) · Journal de Chirurgie · doi:10.1016/s0021-7697(08)74685-4 · Cited by 5
Newer drugs in the management of diabetes mellitus
Deshmukh, V., Motghare, V. M., Padwal, S. L., Jaykare, S., Patil, J., & Pise, H. (2013) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20130102 · Cited by 3
López-Jaramillo, P. A., Velandia, C., Castillo, G., Sánchez, T. E. A., & Álvarez, J. (2013) · Revista Colombiana de Cardiología · doi:10.1016/s0120-5633(13)70072-x · Cited by 5
Choi, K., Lee, J. C., Oh, T. J., Kim, M., Kim, H. C., Cho, Y. M., & Kim, S. (2015) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2015.2465156 · Cited by 3
“During IIGI study, the glucose infusion rates are determined using the manual ad-hoc method [11], [15]–[20] by regularly evaluating the difference between the current and target glucose levels.”
MethodCarnovale, V., Pilon, G., Britten, M., Bazinet, L., & Couillard, C. (2016) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2016.1157139 · Cited by 3
“significantly impaired in T2D patients (Nauck et al. 1986), the possibility of developing incretin-based”
BackgroundPostprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes
Matthews, J. E., Reinhardt, R. R., & Carr, M. C. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1174565 · Cited by 3
The Pathobiology of Diabetes Mellitus
Jenkins, A. J., O'Neal, D. N., Nolan, C. J., & Januszewski, A. S. (2016) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-45307-1_1 · Cited by 3
Metadata
- Authors
- Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W.
- ORCID
- Nauck, M.
- Venue
- Diabetologia
- Published
- 1986-01
- Volume
- 29
- Issue
- 1
- Pages
- 46-52
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2054564814
- Cited by
- 1,307
- References
- 40
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 45 · 2023: 38 · 2022: 53 · 2021: 46 · 2020: 44 · 2019: 60 · 2018: 41 · 2017: 47 · 2016: 65 · 2015: 63 · 2014: 82 · 2013: 86 · 2012: 74
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, incretin effect, insulin secretion, C-peptide, glucose-dependent insulinotropic polypeptide, oral glucose tolerance, intravenous glucose infusion, hepatic insulin extraction, immunoreactive insulin
- MeSH terms
- Adult, Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucose, Glucose Tolerance Test, Humans, Infusions, Parenteral, Insulin, Male, Middle Aged, Pancreas
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.